Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pangaea OncologyXMAD:PANG 60 3-Year ROIIC % is -16.33 as of Dec. 2025. GuruFocus rates XMAD:PANG with a GF Score™ of 60/100 and a GF Value™ of €2.19 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 203 Medical Diagnostics & Research companies, Pangaea Oncology ranks worse than 67.49% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Pangaea Oncology's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was -16.33%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Pangaea Oncology's 3-Year ROIIC % or its related term are showing as below:
XMAD:PANG's 3-Year ROIIC % is ranked worse than 67.49% of 203
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.22
vs XMAD:PANG: -16.33
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Pangaea Oncology 3-Year ROIIC % Related Terms
Pangaea Oncology 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Pangaea Oncology's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XMAD:PANG vs TMO, DHR, IDXX: 3-Year ROIIC % Comparison
For the Diagnostics & Research subindustry, Pangaea Oncology's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pangaea Oncology 3-Year ROIIC % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Pangaea Oncology's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Pangaea Oncology's 3-Year ROIIC % falls into.
Pangaea Oncology's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -3.227588 (Dec. 2025) - -2.108981 (Dec. 2022) )
/
( 25.51 (Dec. 2025) - 18.662 (Dec. 2022) )
=
-1.118607
/
6.848
=
-16.33%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Pangaea Oncology (XMAD:PANG) has a 3-Year ROIIC % of -16.33 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Pangaea Oncology and its competitors. According to the industry distribution chart, Pangaea Oncology ranks #137 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 67.5%.
Is Pangaea Oncology's 3-Year ROIIC % too high?
Pangaea Oncology's current 3-Year ROIIC % is -16.33. Based on the distribution chart, Pangaea Oncology ranks #137 out of 203 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Pangaea Oncology has a GF Score™ of 60/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pangaea Oncology's 3-Year ROIIC % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Pangaea Oncology ranks #137 out of 203 companies for 3-Year ROIIC %. This places Pangaea Oncology in the lower half of its industry. The industry median 3-Year ROIIC % is 0.22. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Medical Diagnostics & Research company?
The median 3-Year ROIIC % among Medical Diagnostics & Research companies is 0.22, based on 203 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Pangaea Oncology and its competitors. For the Medical Diagnostics & Research industry, the median 3-Year ROIIC % is 0.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pangaea Oncology's current 3-Year ROIIC % is -16.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pangaea Oncology stock overvalued right now?
Based on GuruFocus' analysis, Pangaea Oncology (XMAD:PANG) is currently considered Modestly Undervalued. The stock's GF Value™ is €2.19, compared to a current price of €1.55 — trading 29.2% below its estimated fair value. The current 3-Year ROIIC % is -16.33. Pangaea Oncology's overall GF Score™ is 60/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Pangaea Oncology (XMAD:PANG), the current 3-Year ROIIC % is -16.33 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pangaea Oncology (XMAD:PANG) Overvalued in 2026?
Based on GuruFocus' analysis, Pangaea Oncology stock appears to be undervalued.
The current stock price of €1.55 is trading 29.2% below its estimated GF Value™ of €2.19.
GuruFocus considers Pangaea Oncology to be Modestly Undervalued.
Key valuation signals for XMAD:PANG:
3-Year ROIIC %: -16.33
GF Value™: €2.19 vs. price of €1.55 (29.2% below fair value)
No single metric tells the full story. See the XMAD:PANG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pangaea Oncology SA is a medical services company. The company provides a wide range of services to cancer patients, as well as global pharmaceutical and biotech clients, in the fields of molecular diagnostics, clinical trials, in vitro drug profiling, dx platform validation, and biomarker discovery. The company has aggregated its operations into two segments, Clinical Care division and Diagnostic and Research and Development services division. Clinical Care division delivers medical oncology services and related activities. Diagnostic and Research and Development services division provides diagnostic and in-vitro services.
60GF Score
Get the complete analysis for XMAD:PANG
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XMAD:PANG has been successfully added to your 
